SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-171257
Filing Date
2023-06-21
Accepted
2023-06-21 17:02:54
Documents
14
Period of Report
2023-06-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d467534d8k.htm   iXBRL 8-K 37858
2 EX-3.1 d467534dex31.htm EX-3.1 202209
3 EX-3.2 d467534dex32.htm EX-3.2 241543
  Complete submission text file 0001193125-23-171257.txt   693037

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA avir-20230616.xsd EX-101.SCH 2860
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20230616_lab.xml EX-101.LAB 17981
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20230616_pre.xml EX-101.PRE 11265
8 EXTRACTED XBRL INSTANCE DOCUMENT d467534d8k_htm.xml XML 3436
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 231030687
SIC: 2834 Pharmaceutical Preparations